Institute
Institute for Clinical Research
Biography
CK is a clinical researcher with a strong background in early-phase trials and bioethics, currently working at Institute for Clinical Research as Technical Head. He has played an instrumental role in strengthening Malaysia’s clinical trial ecosystem, particularly in First-in-Human (FIH) research, and has contributed to the development of national guidelines and regulatory frameworks to enhance trial quality, safety, and ethical compliance.
As a pioneer member of the team that established the Phase 1 Clinical Trial Unit under the Institute for Clinical Research (ICR), Malaysia, CK has been involved in the successful conduct of numerous pharmacological studies. These include investigations into drug bioavailability, drug-drug and food-drug interactions, formulation effects, bioequivalence, and multiple phase 2/3 vaccine trials.
A strong advocate for ethical research practices, CK is actively engaged in VolREthics (Healthy Research Volunteers and Ethics), an initiative dedicated to promoting responsible conduct in healthy volunteer clinical trials and ensuring the protection of participants’ rights, safety, and well-being.
Key Publications
Fisher JA, Bompart F, Montrasio L, Mwale S, Chew CK, Kurundkar SB, et al. A global ethics charter to protect healthy volunteers. The Lancet. 2024;404(10453):651.
Chew, C. K., Wang, R., Bavanandan, S., et al. (2024). Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a noninferiority randomized controlled trial. Npj Vaccines, 9(1), 1-9.
Park K, Chen M, Shin J, Ong GX, Moorthy V, Zhang W, et al. The Selangor Consensus: strengthening clinical trials for local public health in the Western Pacific. The Lancet Regional Health – Western Pacific. 2024;48.
Bompart F, Fisher JA, Allen E, Sevene E, Kumar N, Chew CK, et al. The VolREthics initiative to protect the well-being of healthy volunteers in biomedical research. Nat Med. 2023;29(10):2393-4.
WHO Solidarity Trial Consortium (2022). "Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses." The Lancet 399(10339): 1941-1953.
Connect with CK